LifeMD, Inc.
$4.82
The Read: LifeMD’s stock surged about 39% after Q4 2025 on strong adjusted EBITDA growth, strategic divestment, and GLP-1 expansion optimism, but then fell about 19% post-Q1 2026 due to a larger-than-expected EPS loss despite revenue and margin gains.
Price
Overlays
Panel
LFMD
Hover to view data
No Data